Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

This latest pipeline guide Acute Lymphocytic Leukemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 3, 58, 52, 2, 69 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 1, 15, 19, 13, 3 and 1 molecules, respectively.

Key Topics Covered

  1. Introduction
  2. Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview
  3. Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Development
  4. Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment
  5. Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development
  6. Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug Profiles
  7. Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects
  8. Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products
  9. Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones
  10. Appendix

Companies Mentioned

  • 4SC AG
  • AbbVie Inc
  • Ariad Pharmaceuticals Inc
  • Array BioPharma Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Bristol-Myers Squibb Co
  • Calithera Biosciences Inc
  • CanBas Co Ltd
  • CARsgen Therapeutics Ltd
  • Cyclacel Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Deciphera Pharmaceuticals LLC
  • Eli Lilly and Co
  • Formula Pharmaceuticals Inc
  • Gamida Cell Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • ImmunoGen Inc
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • NBE-Therapeutics AG
  • Nimbus Therapeutics LLC
  • Nohla Therapeutics Inc
  • Novartis AG
  • OncoTherapy Science Inc
  • Pfenex Inc
  • Pfizer Inc
  • Pharma Mar SA
  • Polyphor Ltd
  • Protheragen Inc
  • Sanofi
  • Sareum Holdings Plc
  • Seattle Genetics Inc
  • Shire Plc

For more information about this report visit https://www.researchandmarkets.com/research/vb74gb/acute_lymphocytic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs